Renamed to Eterna Therapeutics Inc. (NASDAQ:ERNA)
BTX - Brooklyn ImmunoTherapeutics, Inc.
NYSE
->
Healthcare
->
Biotechnology
Brooklyn,
United States
Type: Equity
BTX price evolution
BTX
| (in millions $) | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 | 30 Oct 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $19.41 | $23.5 | $16.98 | $24.38 |
| Short term investments | ||||
| Net receivables | $0.69 | $0.83 | $0.68 | $0.02 |
| Inventory | ||||
| Total current assets | $21.93 | $25.14 | $18.77 | $25.76 |
| Long term investments | ||||
| Property, plant & equipment | $2.46 | $1.4 | $4.24 | $0.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $13.64 | |||
| Total investments | ||||
| Total assets | $26.9 | $35.38 | $32.43 | $39.39 |
| Current liabilities | ||||
| Accounts payable | $1.48 | $1.11 | $1.75 | $1 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.12 | $3.68 | $3.68 | $4.56 |
| Long term debt | ||||
| Total noncurrent liabilities | $21.79 | |||
| Total debt | ||||
| Total liabilities | $12.12 | $18.06 | $25.93 | $26.35 |
| Shareholders' equity | ||||
| Retained earnings | -$153.48 | -$150.08 | -$159.7 | -$151.23 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.98 | $0.78 | $3.26 | $23.59 |
| Short term investments | ||||
| Net receivables | $0.68 | $0.12 | $1.2 | $3.72 |
| Inventory | ||||
| Total current assets | $18.77 | $1.72 | $6.07 | $36.36 |
| Long term investments | ||||
| Property, plant & equipment | $4.24 | $0.5 | $2.82 | $5.83 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.02 | $8.05 | $65.3 | |
| Total investments | ||||
| Total assets | $32.43 | $3.75 | $14.13 | $101.66 |
| Current liabilities | ||||
| Accounts payable | $1.75 | $0.27 | $0.83 | $6.46 |
| Deferred revenue | $0.08 | $0.46 | $0.04 | |
| Short long term debt | ||||
| Total current liabilities | $3.68 | $2.36 | $6.09 | $6.81 |
| Long term debt | $0.53 | $0.02 | $2.77 | |
| Total noncurrent liabilities | $0.53 | $2.94 | $2.6 | |
| Total debt | ||||
| Total liabilities | $25.93 | $2.89 | $9.03 | $9.41 |
| Shareholders' equity | ||||
| Retained earnings | -$159.7 | -$135.89 | -$131.46 | -$261.86 |
| Other shareholder equity | -$0.21 | -$0.19 | -$0.17 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 | 30 Oct 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $7.12 | $5 | $86.33 | |
| Operating income | -$86.33 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.3 | $0 | ||
| Net income | ||||
| Net income | -$3.4 | -$9.38 | -$86.06 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.8 | $19.81 | $4.99 | |
| Cost of revenue | ||||
| Gross Profit | $2.89 | $12.32 | $4.69 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $27.25 | $10.11 | $14.57 | $46.78 |
| Operating income | -$6.31 | -$1.76 | -$41.8 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | -$0.01 | $0.03 | -$0.35 |
| Interest expense | -$0.07 | $0.14 | $0.25 | -$0.71 |
| Net income | ||||
| Net income | -$122.31 | -$4.42 | -$2.05 | -$45.99 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 | 30 Oct 2021 |
|---|---|---|---|---|
| Net income | -$113.84 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$16.66 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.13 | -$0.05 | -$22.74 | -$22.59 |
| Financing activities | ||||
| Dividends paid | -$0.01 | -$0.01 | ||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $11.98 | $11.99 | $61.59 | $62 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $2.42 | $6.51 | $15.36 | $22.75 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Net income | -$4.42 | -$2.05 | -$45.99 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$3.89 | $2.74 | -$30.88 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$22.74 | $0.96 | -$1.06 | $11.82 |
| Financing activities | ||||
| Dividends paid | -$0.01 | -$0.02 | -$0.02 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $61.59 | $0.29 | -$1.1 | $5.77 |
| Effect of exchange rate | $0.01 | $0.04 | $0.01 | |
| Change in cash and equivalents | $15.36 | -$2.63 | $0.62 | -$13.29 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 57.47M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.34 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.08 |
| Quick ratio | N/A |